RBCC and N3D Continue Strong Promotional Push With MAD Scientist Contest

  RBCC and N3D Continue Strong Promotional Push With MAD Scientist Contest  Business Wire  NOKOMIS, Fla. -- September 18, 2013  As part of their ongoing efforts to publicize the breakthrough capabilities of the new Bio-Assembler 3D cell culturing system, Rainbow Coral Corp. (OTCBB: RBCC) and its joint venture partner Nano3D Biosciences (n3D) will reanimate last year’s highly successful MAD Scientist Contest to help introduce a new crop of bio-researchers to the device.  The MAD Scientist Contest is an inventive discovery competition challenging participants to illustrate how 3-D, levitated cultures improve data and achieve results impossible with other cell-culturing systems. Contestants will vie for thousands of dollars in prizes and grants with experiments exhibiting the in-vivo-like characteristics of cell cultures created using n3D's magnetic levitation and nanoparticle assembly tech.  The top cash prize for 2012 was awarded to Hamsa Jaganathan, Ph.D., of the Methodist Hospital Research Institute for her amazing model of a breast tumor microenvironment, created by co-culturing breast cancer cells and fibroblasts. In addition to inspiring outside-the-box thinking among cellular biologists, the MAD Scientist Contest will also serve to introduce n3D's Bio-Assembler system to the young scientists who will lead cellular research into the future.  Rainbow BioSciences acquired an equity interest in n3D last year, positioning the company to participate in the potentially impressive upside in store for n3D. The MAD Scientist Contest promotion is central to n3D and RBCC's ongoing efforts to build strong awareness and interest in the Bio-Assembler among researchers across a broad spectrum of scientific and research disciplines.  Rainbow Biosciences is dedicated to the marketing and development of new medical and research technology innovations designed to help capture a growing share of a booming biotech industry alongside Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN).  For more information on RBCC’s partnership with n3D and other biotech initiatives, please visit www.rainbowbiosciences.com/investors.html.  About Rainbow Biosciences  Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB:RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visitwww.RainbowBioSciences.com. For investment information and performance data on the Company, please visitwww.RainbowBioSciences.com/investors.html.  Notice Regarding Forward-Looking Statements  Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.  Contact:  Rainbow Coral Corp. Patrick Brown, 850-269-7230 President and CEO info@rainbowcoral.com  
Press spacebar to pause and continue. Press esc to stop.